The importance of lipoprotein(a) in pathogenesis of the high risk unstable angina;Yüksek riskli kararsiz anginanin patogenezinde lipoprotein(a)'nin önemi

Anadolu Kardiyoloji Dergisi

Volumn 6, Issue 1, 2006, Pages 13-17

  Yazici, Mustafa ^a   Demircan, Sabri ^a   Ibrahimli, Firdovsi ^a   Aksakal, Emre ^a   Şahin, Mahmut ^a   Saǧkan, Olcay ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Lipoprotein(a); Myocardial injury; Troponin I; Unstable angina

Indexed keywords

C REACTIVE PROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TROPONIN I;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION FUNCTION; DISEASE SEVERITY; HEART MUSCLE INJURY; HIGH RISK PATIENT; HUMAN; INTRACARDIAC THROMBOSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; RISK ASSESSMENT; SCORING SYSTEM; THORAX PAIN; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY THROMBOSIS; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TROPONIN I;

EID: 33645054032     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolisation culminating in total vascular occlusion. Circulation 1985; 71: 699-8.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326; 310-8.
3. Terres W, Kummel P, Sudrow A, Reuter H, Meinertz T, Hamm CW. Enhanced coagulation activation in troponin T positive unstable angina pectoris. Am Heart J 1998; 135: 281-6.
4. Hamm CW, Ravkilde J, Gerhardt W, Jorgensen P, Peheim E, Ljungdahl L, et al. The prognostic value of serum Troponin T in unstable angina. N Engl J Med 1992; 327: 146-50.
5. Benamer H, Steg PG, Benessiano J, Vicaut E, Gaultier CJ, Aubry P, et al. Elevated cardiac troponin I predicts a high risk angiographic anatomy of the culprit lesion in unstable angina. Am Heart J 1999; 137: 815-20.
6. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992; 267: 4143-51.
7. Loscalzo J, Weinfeld M, Fless G, Scanu AM. Lipoprotein(a), fibrin binding and plazminojen activation. Arteriosclerosis 1990; 10: 240-5.
8. Seed M, Doherty E, Stubbs P. Lipoprotein(a): a prothrombotic risk factor for coronary artery disease. J Cardiovasc Risk 1995; 2: 206-15.
9. Avellone G, Di Garbo V, Abruzzese G, Campisi D, Giannola G, De Simone R, et al. Elevated levels of lipoprotein (a) in patients suffering from myocardial infarction with carotid atherosclerotic lesions. Blood Coagul Fibrinolysis 1999; 10: 331-9.
10. Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995; 1: 256-9.
11. Sangrar W, Bajzar L, Nesheim ME, Koschinsky ML. Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of t-PA-mediated Glu-plasminogen activation. Biochemistry 1995; 34: 5151-7.
12. World Health Organization. Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature. Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 1979; 59: 607-9.
13. Almeda FQ., Calvin JE, Parrillo JE, Sun FG, Barron JT. Prevalence of angiographically significant stenosis in patients with chest pain and an elevated troponin I level and normal creatine kinase and creatine kinase-MB levels. Am J Cardiol 2001; 87: 1286-9.
14. Sanchis J, Bodi V, Llacer A, Facila L, Nunez J, Bertomeu V, et al. Usefulness of concomitant myoglobin and troponin elevation as a biochemical marker of mortality in non-ST-segment elevation acute coronary syndromes. Am J Cardiol 2003; 91: 448-51.
15. Wang CH, Kuo LT, Hung MJ, Cherng WJ. Coronary vasospasm as a possible cause of elevated cardiac troponin I in patients with acute coronary syndrome and insignificant coronary artery disease. Am Heart J 2002; 144: 275-1.
16. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
17. Ohnishi N, Iwasaki K, Kusachi S, Hirami R, Matano S, Ohnishi H, et al. Low incidence of minor myocardial damage associated with balloon coronary stenting detected by serum troponin T comparable to that with balloon coronary angioplasty. Jpn Heart J 1998; 39: 139-46.
18. Mair J, Dienstl F, Puschendorf B. Cardiac Troponin T in the diagnosis of myocardial injury. Crit Rev Clin Lab Sci 1992; 29: 31-57.
19. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1985; 73: 418-27.
20. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Eng J Med 1996; 335: 1342-9.
21. Olatidoye AG, Wu AHB, Fong YJ, Waters D. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol 1998; 81: 1405-10.
22. Lüscher MS, Thygesen K, Ravkilde J, Heickendorff L, for the TRIM Study Group. Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. Circulation 1997; 96: 2578-85.
23. Bugiardini R, Pozzati A, Borghi A, Morgagni GL, Ottani F, Muzi A, et al. Angiographic morphology in unstable angina and its relation to transient myocardial ischemia and hospital outcome. Am J Cardiol 1991; 67: 460-4.
24. Freeman MR, Williams AE, Chisholm RJ, Armstrong PW. Intracoronary thrombus and complex morphology in unstable angina. Circulation 1989; 80: 17-23.
25. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-82.
26. Burke AP, Farb A, Malcom GT, Liang Y, Smialek J, Virmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998; 97: 2110-6.
27. Zampoulakis JD, Kyriakousi AA, Poralis KA, Karaminas NT, Palermos ID, Chimonas ET, et al. Lipoprotein(a) is related to the extent of lesions in the coronary vasculature and to unstable coronary syndromes. Clin Cardiol 2000; 23: 895-900.
28. Williams JK, Bellinger DA, Nichols TC, Griggs TR, Bumol TF, Fouts RL, et al. Occlusive arterial thrombosis in cynomolgus monkeys with varying plasma concentrations of lipoprotein(a). Arterioscler Thromb 1993; 13: 548-54.
29. Ichinose A, Suzuki K, Saito T. Apolipoprotein (a) and thrombosis: molecular and genetic bases of hyperlipoprotein(a)-emia. Semin Thromb Hemost 1998; 24: 237-43.
30. Angles-Cano E. High antifibrinolytic activity of Lipoprotein(a) containing small apolipoprotein(a) isoforms. Circulation, 2000; 102: E184-5.
31. Torres W, Kummel P, Sudrow A, Reuter H, Meinertz T, Hamm CW. Enhanced coagulation activation in troponin T positive unstable angina pectoris. Am Heart J 1998; 135: 281-6.
32. Stubbs P, Seed M, Moseley D, O'Connor B, Collinson P, Noble M. A prospective study of the role of lipoprotein(a) in the pathogenesis of unstable angina, Eur Heart J 1997; 18: 603-7.
33. Srinivasan SR, Dahlen GH, Jarpa RA, Webber LS, Berenson GS. Racial (black/white) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children: Bogalusa Heart Study. Circulation 1991; 84: 160-7.
34. Rainwater DL, McMahan CA, Malcom GT, Scheer WD, Roheim PS, McGill HC Jr, et al. Lipid and apolipoprotein predictors of atherosclerosis in young: Apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects. The PDAY Research Group. Arterioscler Thromb Vasc Biol 1999; 19: 753-61.
35. Amstrong VW, Cromer P, Eberle E, Manke A, Schulze F, Wieland H, et al. The association between serum Lp(a) and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 1986; 62: 249-57.
36. Nielsen LB. Atherogenicity of lipoprotein(a) and oxidized low density lipoprotein: Insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis 1999; 143: 229-43.
37. Scanu AM. Atherothrombogenicity of lipoprotein(a): The debate. Am J Cardiol 1998; 82: 26-33.
38. Mahley RW. Biochemistry and physiology of lipid and lipoprotein metabolism. In: Becker KL, editor. Principles and Practice of Endocrinology and Metabolism. Philadelphia: Lippincott Co; 1990. p. 1219-29.
39. Min WK, Lee JO, Huh JW. Relation between lipoprotein(a) concentrations in patients with acute-phase response and risk analysis for coronary heart disease. Clin Chem 1997; 43: 1891-5.